Credit Suisse Ag Biomarin Pharmaceutical Inc Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Credit Suisse Ag holds 286,650 shares of BMRN stock, worth $19.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

286,650

Previous 311,993 8.12%

Holding current value

$19.1 Million

Previous $30.1 Million 16.77%

% of portfolio

0.02%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$83.81 - $99.0 $2.12 Million - $2.51 Million	-25,343 Reduced 8.12%	286,650 $25 Million
Q4 2023 Feb 08, 2024	SELL	$76.22 - $98.51 $1.96 Million - $2.53 Million	-25,672 Reduced 7.6%	311,993 $30.1 Million
Q3 2023 Nov 13, 2023	SELL	$85.07 - $94.48 $511,185 - $567,730	-6,009 Reduced 1.75%	337,665 $29.9 Million
Q2 2023 Aug 11, 2023	SELL	$86.68 - $100.3 $13.4 Million - $15.6 Million	-155,123 Reduced 31.1%	343,674 $29.8 Million
Q1 2023 May 10, 2023	SELL	$87.74 - $117.27 $733,067 - $979,790	-8,355 Reduced 1.65%	498,797 $48.5 Million
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $1.97 Million - $2.64 Million	24,331 Added 5.04%	507,152 $52.5 Million
Q3 2022 Nov 10, 2022	BUY	$82.16 - $96.94 $3.91 Million - $4.61 Million	47,534 Added 10.92%	482,821 $40.9 Million
Q2 2022 Aug 12, 2022	SELL	$71.48 - $86.85 $5.87 Million - $7.13 Million	-82,125 Reduced 15.87%	435,287 $36.1 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $773,849 - $965,644	10,418 Added 2.05%	517,412 $39.9 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $2.91 Million - $3.71 Million	-40,528 Reduced 7.4%	506,994 $44.8 Million
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $2.98 Million - $3.41 Million	-39,839 Reduced 6.78%	547,522 $42.3 Million
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $500,404 - $561,903	6,627 Added 1.14%	587,361 $49 Million
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $723,311 - $877,788	9,679 Added 1.69%	580,734 $43.9 Million
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $8.62 Million - $10.7 Million	118,701 Added 26.24%	571,055 $50.1 Million
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $1.27 Million - $2.31 Million	17,642 Added 4.06%	452,354 $34.4 Million
Q2 2020 Aug 12, 2020	BUY	$79.55 - $124.22 $13.4 Million - $21 Million	169,051 Added 63.63%	434,712 $53.6 Million
Q1 2020 May 13, 2020	SELL	$71.37 - $96.85 $3.73 Million - $5.06 Million	-52,195 Reduced 16.42%	265,661 $22.4 Million
Q4 2019 Feb 12, 2020	BUY	$64.27 - $86.37 $889,303 - $1.2 Million	13,837 Added 4.55%	317,856 $26.9 Million
Q3 2019 Nov 12, 2019	BUY	$67.4 - $85.11 $758,789 - $958,168	11,258 Added 3.85%	304,019 $20.5 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $1.98 Million - $2.32 Million	24,679 Added 9.21%	292,761 $25.1 Million
Q1 2019 May 14, 2019	SELL	$84.2 - $98.62 $3.61 Million - $4.22 Million	-42,816 Reduced 13.77%	268,082 $23.8 Million
Q4 2018 Feb 13, 2019	SELL	$80.14 - $106.07 $7.92 Million - $10.5 Million	-98,823 Reduced 24.12%	310,898 $26.5 Million
Q3 2018 Nov 13, 2018	BUY	$93.92 - $105.72 $14.4 Million - $16.3 Million	153,851 Added 60.13%	409,721 $39.7 Million
Q2 2018 Aug 14, 2018	SELL	$76.01 - $99.03 $3.78 Million - $4.92 Million	-49,705 Reduced 16.27%	255,870 $24.1 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $3.77 Million - $4.49 Million	48,485 Added 18.86%	305,575 $24.8 Million
Q4 2017 Feb 14, 2018	SELL	$80.76 - $95.13 $10.3 Million - $12.1 Million	-127,328 Reduced 33.12%	257,090 $22.9 Million
Q3 2017 Nov 14, 2017	SELL	$80.6 - $94.95 $4.01 Million - $4.73 Million	-49,788 Reduced 11.47%	384,418 $35.8 Million
Q2 2017 Aug 14, 2017	BUY	N/A	434,206	434,206 $39.4 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account